Annonce • Apr 17
Orthocell Limited Secures Approval for Remplir Nerve Repair Device to Be Used Across United States Department of Defence and Veterans Affairs Hospital Networks Orthocell Limited had secured approval for its Remplir nerve repair device to be used across the United States Department of Defence and Veterans Affairs hospital networks. This approval provides access to approximately 51 DoD military hospitals and 170 VA medical centres across the United States, representing a significant milestone in expanding Orthocell's access to the U.S. market. Orthocell's established U.S. distributor network, which currently covers 17 states, will now target military and VA surgeons operating within these hospital systems. A significant portion of these facilities could be serviced by the Company's existing distribution footprint, supporting efficient market penetration. This expansion into the defence setting follows the recent clinical use of Remplir in 23 surgical procedures on injured soldiers in Ukraine, across both primary and secondary nerve repair applications. The Ukraine experience demonstrates the real-world performance of Remplir in a conflict environment and highlights key attributes of the device, including its portability, ease of use, and suitability for treating major traumatic injuries commonly encountered in military settings. Orthocell believes this validation further supports Remplir's applicability within defence healthcare systems and reinforces its potential to address the needs of military surgeons treating complex nerve injuries. Annonce • Apr 14
Orthocell Limited to Report Q3, 2026 Results on Apr 20, 2026 Orthocell Limited announced that they will report Q3, 2026 results on Apr 20, 2026 Annonce • Nov 20
Orthocell Limited Announces Adoption of Remplir by Australian Urologists Orthocell Limited announced adoption of Remplir™? by Australian urologists is accelerating with the product increasingly being used during prostate cancer surgery in a promising new application aimed at reducing post-surgical complications from peripheral nerve injury. Remplir has now been used in 100 surgical cases to assist in improving recovery of erectile function and urinary continence post-surgery. This estimate is based on ~ 115,000 prostatectomies performed annually in the U.S., the majority of which are conducted automatically. To capitalise on this opportunity, the Company is establishing a commercialisation advisory board and investing in additional research to strengthen the scientific evidence base for this innovative peripheral nerve repair application, ahead of a targeted U.S. product launch in the medium term. Orthocell is also collating clinical data on initial patients who underwent radical prostatectomies with Remplir in Australia. This data will be released once compiled and will support the scientific foundation for formal product launch in existing approved markets. Annonce • Nov 14
Orthocell Limited has completed a Follow-on Equity Offering in the amount of AUD 30.000001 million. Orthocell Limited has completed a Follow-on Equity Offering in the amount of AUD 30.000001 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 22,846,154
Price\Range: AUD 1.3
Discount Per Security: AUD 0.065
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 230,770
Price\Range: AUD 1.3
Discount Per Security: AUD 0.065
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing Annonce • Sep 16
Orthocell Limited Announces Nerve-Sparing Prostate Cancer Surgery Orthocell Limited announced its nerve repair device, Remplir, has been introduced to Urologists in Australia for use in nerve-sparing Robotic-Assisted Radical Prostatectomies (RARP). Remplir has been used in approximately 40 surgical cases to assist in improving recovery of erectile function and urinary continence post-surgery. Orthocell is collating clinical data on initial patients who underwent radical prostatectomies with Remplir in Australia and will release the clinical data once available. The Company will also invest in further clinical studies to build evidence and assist medical education initiatives to drive further adoption of Remplir in this market. Summary Points: Australian urologists are using Remplir during prostate cancer surgery in a promising new application aimed at reducing post-surgical complications due to peripheral nerve injury -- a development with potential for globally significant impact. Currently up to 80% of men experience erectile dysfunction, and up to 35% suffer from urinary incontinence, after radical prostatectomy due to damage of the peripheral nerves in the neurovascular bundle (NVB) surrounding the prostate. Despite procedures aimed at preserving nerve function (i.e. nerve-sparing), and with the enhanced surgical precision offered by robotic assisted radical prostatectomies (RARP), there remains a significant risk of post-surgical erectile dysfunction and/or urinary incontinence. Similar to peripheral nerve repair procedures that restore function to the arms and legs, Remplir can be used to protect the NVB from damage and promote restoration of normal nerve function. Remplir has been used In approximately 40 nerve-sparing RARP by urologists across Australia. Orthocell is currently collaborating with urologists to collect and analyse retrospective outcome data from these nerve-sparing procedures using Remplir, with data to be released once available. The Company also intends to invest in further research to build evidence and assist medical Education initiatives related to this innovative use of Remplir for peripheral nerve repair. The Company believes the use of Remplir in nerve-sparing RARP represents a significant opportunity to expand Remplir's Total Addressable Market. Remplir rollout in the USD 1.6 Billion US market continues to build momentum, with in-country representatives making significant progress working with distributors to gain hospital approvals, on-board surgeons and establish active accounts. Initial US surgical cases continue to build. Nerve repair market sizes estimated using referenced papers from both US and OUS databases and studies. Annonce • Sep 11
Orthocell Limited, Annual General Meeting, Nov 06, 2025 Orthocell Limited, Annual General Meeting, Nov 06, 2025. Reported Earnings • Aug 31
Full year 2025 earnings released: AU$0.038 loss per share (vs AU$0.036 loss in FY 2024) Full year 2025 results: AU$0.038 loss per share (further deteriorated from AU$0.036 loss in FY 2024). Revenue: AU$7.55m (up 42% from FY 2024). Net loss: AU$8.57m (loss widened 19% from FY 2024). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 44% per year, which means it is tracking significantly ahead of earnings growth. Annonce • Oct 31
Orthocell Limited has completed a Follow-on Equity Offering in the amount of AUD 17 million. Orthocell Limited has completed a Follow-on Equity Offering in the amount of AUD 17 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 28,166,667
Price\Range: AUD 0.6
Discount Per Security: AUD 0.03
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 166,666
Price\Range: AUD 0.6
Discount Per Security: AUD 0.03
Transaction Features: Subsequent Direct Listing Annonce • Oct 25
Orthocell Limited has filed a Follow-on Equity Offering in the amount of AUD 17 million. Orthocell Limited has filed a Follow-on Equity Offering in the amount of AUD 17 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 28,166,667
Price\Range: AUD 0.6
Discount Per Security: AUD 0.03
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 166,666
Price\Range: AUD 0.6
Discount Per Security: AUD 0.03
Transaction Features: Subsequent Direct Listing Annonce • Oct 04
Orthocell Limited, Annual General Meeting, Nov 29, 2024 Orthocell Limited, Annual General Meeting, Nov 29, 2024. Reported Earnings • Aug 31
Full year 2024 earnings released: AU$0.036 loss per share (vs AU$0.032 loss in FY 2023) Full year 2024 results: AU$0.036 loss per share (further deteriorated from AU$0.032 loss in FY 2023). Revenue: AU$5.32m (up 25% from FY 2023). Net loss: AU$7.18m (loss widened 15% from FY 2023). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Annonce • Mar 01
Orthocell Limited has completed a Follow-on Equity Offering in the amount of AUD 3.500001 million. Orthocell Limited has completed a Follow-on Equity Offering in the amount of AUD 3.500001 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 9,459,461
Price\Range: AUD 0.37
Transaction Features: Subsequent Direct Listing New Risk • Feb 29
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 5.1% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (5.8% increase in shares outstanding). Revenue is less than US$5m (AU$4.8m revenue, or US$3.1m). Market cap is less than US$100m (AU$88.7m market cap, or US$57.6m). Annonce • Feb 23
Orthocell Limited has filed a Follow-on Equity Offering in the amount of AUD 3.5 million. Orthocell Limited has filed a Follow-on Equity Offering in the amount of AUD 3.5 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 9,459,460
Price\Range: AUD 0.37
Transaction Features: Subsequent Direct Listing Annonce • Dec 22
Orthocell Limited Announces Changes to its Board Orthocell Limited announced that founding Board member and former Chairman, Dr. Stewart Washer, has retired from the Company's Board. Dr. Washer has completed the transition from his previous role as the long-standing Chair and has fully handed over the reins to new Chairman John Van Der Wielen. Stewart made the decision to retire from the Orthocell Board after having served almost 10 years to allow him to pursue other interests. Orthocell Board now has five Directors comprising four Non-Executive Directors and one Executive Director. The recent appointment of Professor Fiona Wood, independent non-executive Director Dr. Ravi Thadhani and Chairman Mr. John Van Der Wielen to the Orthocell Board, has strengthened the leadership team as the Company prepares for the next phase of development and commercialisation of its unique medical devices and cellular therapies. Annonce • Oct 26
Orthocell Limited Provides Commercial Revenue Guidance for the Full Year 2023 Orthocell Limited provided commercial revenue guidance for the full year 2023. For the period, the company expects commercial revenue to in the range of $51 million to $53 million. Annonce • Oct 25
Orthocell Limited Announces Board Changes Orthocell Limited announced the appointment of Professor Fiona Wood AM to the Orthocell Board. This coincides with the retirement of Mr. Qi Xiao Zhou, who has served as a Member of Orthocell’s Board since 2012 and the transition of Dr. Stewart Washer from Executive Director to Non-Executive Director. All changes detailed above will be effective 01 November, 2023. The appointment of Professor Wood follows the recent appointment of experienced Chairman Mr. John Van Der Wielen, and independent Non-Executive USA based Director Dr. Ravi Thadhani. Professor Fiona Wood is a well-known and highly respected West Australian, and Australian National Living Treasure, with more than 30 years’ experience as a plastic and reconstructive surgeon. Professor Wood was named Western Australian Citizen of the Year in 2003 and 2004, Australian of the Year in 2005 and Member of the Order of Australia (AM) in 2003 for her contribution to Medicine in the field of burns. Her revolutionary “spray-on skin” treatment of serious burns, invented with colleague Marie Stoner, uses a patient’s own skin cells to help restore damaged skin and significantly reduce permanent scarring. This treatment was instrumental in saving many lives in the aftermath of the Bali bombing in 2002. Professor Wood is currently a Consultant Plastic Surgeon at Fiona Stanley Hospital and Perth Children’s Hospital, and the Winthrop Professor of Surgery at the University of Western Australia. Professor Wood is co-founder of the Wood Foundation, which continues her research into the treatment of burns and is a Board member of the Royal Flying Doctor Service, amongst others. Following Professor Woods’s appointment and the resignation of Mr. Zhou, the Orthocell Board has six Directors comprising four Non-Executive Directors and two Executive Directors. With the experienced Board and management team, market leading products and strong balance sheet, the Company is well positioned to grow product sales alongside distribution partners, BioHorizons and Device Technologies, and to execute its US market access program and commercialisation strategies for its breakthrough nerve repair medical device. Board Change • Oct 06
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 8 experienced directors. 2 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Non-Executive Chairman John Van Der Wielen was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Annonce • Sep 22
Orthocell Limited Announces Board Changes Orthocell Limited announced that Professor Lars Lidgren is retiring from the Orthocell Board, effective from 30 September 2023 and Ms Leslie Wise is taking a temporary leave of absence for personal reasons, effective immediately. Annonce • Sep 05
Orthocell Limited, Annual General Meeting, Oct 31, 2023 Orthocell Limited, Annual General Meeting, Oct 31, 2023. Reported Earnings • Sep 01
Full year 2023 earnings released: AU$0.032 loss per share (vs AU$0.047 loss in FY 2022) Full year 2023 results: AU$0.032 loss per share (improved from AU$0.047 loss in FY 2022). Revenue: AU$4.24m (up 177% from FY 2022). Net loss: AU$6.25m (loss narrowed 31% from FY 2022). Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has fallen by 1% per year. New Risk • Aug 31
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 16% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Revenue is less than US$5m (AU$1.6m revenue, or US$1.0m). Market cap is less than US$100m (AU$79.9m market cap, or US$51.8m). Annonce • May 30
Orthocell Limited Appoints John Van Der Wielen as Independent Non-Executive Chairman, Effective 1 June 2023 Regenerative medicine company Orthocell Limited announced the appointment of John Van Der Wielen as independent Non-Executive Chairman, effective 1 June 2023. Dr. Stewart Washer, who has served as Executive Chairman since April 2014, will transition to Executive Director. The appointment of Mr. Van Der Wielen follows the recent addition of globally recognised healthcare executive Dr. Ravi Thadhani to the Orthocell Board and will further strengthen the leadership team as the Company prepares for the next phase of development and commercialisation of its unique medical devices and cellular therapies. As a senior financial services professional, Mr. Van Der Wielen has over 35 years' international experience in wealth management, private banking, investments, and insurance, in the UK, Luxembourg, Malaysia and Australia. He has held senior executive positions with several national and global financial services groups. Most recently Mr. Van Der Wielen was the CEO and MD of HBF Health Ltd. for over five years. HBF has revenue of over 1.6 billion dollars and in a recent independent consumer survey was named Australia's most trusted brand in private health insurance. Mr. Van Der Wielen's other previous executive positions include CEO (UK & International) of Friends Life UK, Managing Director (Wealth) of ANZ, CEO of Clerical Medical, Halifax Life & Heidelberger Leben and CEO of Lloyds Banking Group/HBOS Plc. Mr. Van Der Wielen has held numerous directorships and advisory positions, including roles as Senior Adviser to Blackstone. He has served as Chairperson of Kyckr, Non-Executive Director of Partners Life, Non- Executive Director of Friends Provident International and Non-Executive Director of Lombard International Assurance. Mr. Van Der Wielen has significant expertise overseeing and chairing large funds management and investment committees, as well as leading on acquisitions, integration and restructuring programs. Mr. Van Der Wielen is currently Non-Executive Director, of the Blackstone owned Crown Resorts and Chair of Crown Perth, and Non-Executive Director of the Royal Flying Doctor Service WA. He is a Senior Adviser to Appian Capital Advisory LLP and was recently appointed by the Western Australian Government to Chair its Future Health Research and Innovation Fund (FHRI). The FHRI is a sovereign wealth fund, with a purpose is to improve, through research and innovation, the health and prosperity of Western Australians, the sustainability of the health system and to advance the State's standing as a leader in research and innovation. Mr. Van Der Wielen holds an MBA from the University of Western Australia, has studied at London Business School and Oxford University, and is a Fellow of the Australian Institute of Company Directors. Reported Earnings • Mar 03
First half 2023 earnings released: AU$0.021 loss per share (vs AU$0.024 loss in 1H 2022) First half 2023 results: AU$0.021 loss per share (improved from AU$0.024 loss in 1H 2022). Net loss: AU$4.06m (loss narrowed 13% from 1H 2022). Revenue is forecast to grow 70% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Biotechs industry in Australia. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings. Board Change • Nov 17
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non-Executive Director Matt Callahan was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Sep 02
Full year 2022 earnings released: AU$0.047 loss per share (vs AU$0.048 loss in FY 2021) Full year 2022 results: AU$0.047 loss per share. Net loss: AU$9.11m (flat on FY 2021). Board Change • Apr 28
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non-Executive Director Matt Callahan was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Recent Insider Transactions • Sep 25
CEO, MD & Executive Director recently sold AU$552k worth of stock On the 23rd of September, Paul Anderson sold around 1m shares on-market at roughly AU$0.48 per share. This was the largest sale by an insider in the last 3 months. This was Paul's only on-market trade for the last 12 months. Board Change • Sep 23
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non-Executive Director Matt Callahan was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Sep 07
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 5 non-independent directors. Independent Non-Executive Director Lars Lidgren was the last independent director to join the board, commencing their role in 2007. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 29
Full year 2021 earnings released: AU$0.047 loss per share (vs AU$0.036 loss in FY 2020) Full year 2021 results: Net loss: AU$9.04m (loss widened 47% from FY 2020). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has increased by 18% per year, which means it is tracking significantly ahead of earnings growth. Is New 90 Day High Low • Jan 04
New 90-day high: AU$0.48 The company is up 14% from its price of AU$0.42 on 07 October 2020. The Australian market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 2.0% over the same period. Is New 90 Day High Low • Nov 03
New 90-day low: AU$0.33 The company is down 6.0% from its price of AU$0.34 on 05 August 2020. The Australian market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 1.0% over the same period. 
